These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37691344)

  • 21. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
    Hackshaw MD; Bui CL; Ladner A; Tu N; Islam Z; Ritchey ME; Salas M
    Cancer Treat Res Commun; 2020; 24():100189. PubMed ID: 32673845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
    Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
    Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies in gastroesophageal cancer.
    Kasper S; Schuler M
    Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer.
    Désilets A; Elkhoury R; Gebai A; Tehfe M
    Curr Oncol; 2023 Oct; 30(10):9304-9316. PubMed ID: 37887572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma.
    Lynch E; Duffy AG; Kelly RJ
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
    Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
    Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
    Cheng R; Li B; Wang H; Zeng Y
    Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
    Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
    Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New agents on the horizon in gastric cancer.
    Lordick F; Shitara K; Janjigian YY
    Ann Oncol; 2017 Aug; 28(8):1767-1775. PubMed ID: 28184417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
    Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
    Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
    Ricci AD; Rizzo A; Rojas Llimpe FL; Di Fabio F; De Biase D; Rihawi K
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.